BACKGROUND: Degeneration of xenografts or homografts is a major cause for reoperation in young patients after pulmonary valve replacement. We present the early results of fresh decellularized pulmonary homografts (DPH) implantation compared with glutaraldehyde-fixed bovine jugular vein (BJV) and cryopreserved homografts (CH). METHODS AND RESULTS: Thirty-eight patients with DPH in pulmonary position were consecutively evaluated during the follow-up (up to 5 years) including medical examination, echocardiography, and MRI. These patients were matched according to age and pathology and compared with BJV (n=38) and CH (n=38) recipients. In contrast to BJV and CH groups, echocardiography revealed no increase of transvalvular gradient, cusp thickening, or aneurysmatic dilatation in DPH patients. Over time, DPH valve annulus diameters converge toward normal z-values. Five-year freedom from explantation was 100% for DPH and 86 ± 8% and 88 ± 7% for BJV and CH conduits, respectively. Additionally, MRI investigations in 17 DPH patients with follow-up time >2 years were compared with MRI data of 20 BJV recipients. Both patient groups (DPH and BJV) were at comparable ages (mean, 12.7 ± 6.1 versus 13.0 ± 3.0 years) and have comparable follow-up time (3.7 ± 1.0 versus 2.7 ± 0.9 years). In DPH patients, the mean transvalvular gradient was significantly (P=0.001) lower (11 mm Hg) compared with the BJV group (23.2 mm Hg). Regurgitation fraction was 14 ± 3% and 4 ± 5% in DPH and BJV groups, respectively. In 3 DPH recipients, moderate regurgitation was documented after surgery and remained unchanged in follow-up. CONCLUSIONS: In contrast to conventional homografts and xenografts, decellularized fresh allograft valves showed improved freedom from explantation, provided low gradients in follow-up, and exhibited adaptive growth.
BACKGROUND: Degeneration of xenografts or homografts is a major cause for reoperation in young patients after pulmonary valve replacement. We present the early results of fresh decellularized pulmonary homografts (DPH) implantation compared with glutaraldehyde-fixed bovine jugular vein (BJV) and cryopreserved homografts (CH). METHODS AND RESULTS: Thirty-eight patients with DPH in pulmonary position were consecutively evaluated during the follow-up (up to 5 years) including medical examination, echocardiography, and MRI. These patients were matched according to age and pathology and compared with BJV (n=38) and CH (n=38) recipients. In contrast to BJV and CH groups, echocardiography revealed no increase of transvalvular gradient, cusp thickening, or aneurysmatic dilatation in DPHpatients. Over time, DPH valve annulus diameters converge toward normal z-values. Five-year freedom from explantation was 100% for DPH and 86 ± 8% and 88 ± 7% for BJV and CH conduits, respectively. Additionally, MRI investigations in 17 DPHpatients with follow-up time >2 years were compared with MRI data of 20 BJV recipients. Both patient groups (DPH and BJV) were at comparable ages (mean, 12.7 ± 6.1 versus 13.0 ± 3.0 years) and have comparable follow-up time (3.7 ± 1.0 versus 2.7 ± 0.9 years). In DPHpatients, the mean transvalvular gradient was significantly (P=0.001) lower (11 mm Hg) compared with the BJV group (23.2 mm Hg). Regurgitation fraction was 14 ± 3% and 4 ± 5% in DPH and BJV groups, respectively. In 3 DPH recipients, moderate regurgitation was documented after surgery and remained unchanged in follow-up. CONCLUSIONS: In contrast to conventional homografts and xenografts, decellularized fresh allograft valves showed improved freedom from explantation, provided low gradients in follow-up, and exhibited adaptive growth.
Authors: J Koudy Williams; Elizabeth S Miller; Magan R Lane; Anthony Atala; James J Yoo; James E Jordan Journal: J Cardiovasc Transl Res Date: 2015-09-04 Impact factor: 4.132
Authors: Donal MacGrogan; Guillermo Luxán; Anita Driessen-Mol; Carlijn Bouten; Frank Baaijens; José Luis de la Pompa Journal: Cold Spring Harb Perspect Med Date: 2014-11-03 Impact factor: 6.915
Authors: M Granados; L Morticelli; S Andriopoulou; P Kalozoumis; M Pflaum; P Iablonskii; B Glasmacher; M Harder; J Hegermann; C Wrede; I Tudorache; S Cebotari; A Hilfiker; A Haverich; Sotirios Korossis Journal: J Cardiovasc Transl Res Date: 2017-05-01 Impact factor: 4.132
Authors: Petra E Dijkman; Emanuela S Fioretta; Laura Frese; Francesco S Pasqualini; Simon P Hoerstrup Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Paula Hansen Suss; Victoria Stadler Tasca Ribeiro; Juliette Cieslinski; Letícia Kraft; Felipe Francisco Tuon Journal: Exp Biol Med (Maywood) Date: 2019-01-06
Authors: Igor Tudorache; Alex Calistru; Hassina Baraki; Tanja Meyer; Klaus Höffler; Samir Sarikouch; Christopher Bara; Adelheid Görler; Dagmar Hartung; Andres Hilfiker; Axel Haverich; Serghei Cebotari Journal: Tissue Eng Part A Date: 2013-04-26 Impact factor: 3.845
Authors: Iyore A James; Tai Yi; Shuhei Tara; Cameron A Best; Alexander J Stuber; Kejal V Shah; Blair F Austin; Tadahisa Sugiura; Yong-Ung Lee; Joy Lincoln; Aaron J Trask; Toshiharu Shinoka; Christopher K Breuer Journal: Tissue Eng Part C Methods Date: 2015-05-29 Impact factor: 3.056